Comparing Aurinia Pharmaceuticals (NASDAQ:AUPH) & Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA – Get Free Report) and Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Risk and Volatility

Coya Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Coya Therapeutics and Aurinia Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coya Therapeutics 1 0 5 0 2.67
Aurinia Pharmaceuticals 0 3 2 1 2.67

Coya Therapeutics presently has a consensus price target of $15.00, suggesting a potential upside of 379.23%. Aurinia Pharmaceuticals has a consensus price target of $17.33, suggesting a potential upside of 10.19%. Given Coya Therapeutics’ higher possible upside, research analysts plainly believe Coya Therapeutics is more favorable than Aurinia Pharmaceuticals.

Earnings and Valuation

This table compares Coya Therapeutics and Aurinia Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coya Therapeutics $7.95 million 9.24 -$21.23 million ($1.39) -2.25
Aurinia Pharmaceuticals $283.05 million 7.45 $287.20 million $2.29 6.87

Aurinia Pharmaceuticals has higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Coya Therapeutics and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Coya Therapeutics -643.44% -71.48% -63.57%
Aurinia Pharmaceuticals 97.68% 22.99% 17.99%

Insider and Institutional Ownership

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Aurinia Pharmaceuticals beats Coya Therapeutics on 10 of the 14 factors compared between the two stocks.

About Coya Therapeutics

(Get Free Report)

Coya Therapeutics is a clinical-stage biotechnology company developing therapies that aim to enhance the function of regulatory T cells, immune cells that help control inflammation. Its research focuses on potential treatments for neurodegenerative and other diseases associated with inflammation and immune dysfunction. The company’s development programs include biologic and cell-based approaches, with candidates under investigation for conditions including amyotrophic lateral sclerosis (ALS). These therapies remain in development; Coya does not have an approved commercial product.

About Aurinia Pharmaceuticals

(Get Free Report)

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs. Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy. Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis.

Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.